Forte Biosciences (FRA:37T) Other Current Receivables: €0.57 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:37T Forte Biosciences Inc FRA:37T
35 GF Score
Price €43.20
! 3 Warning Signs
View Full Analysis

What is Forte Biosciences Other Current Receivables?

Forte Biosciences FRA:37T +10.20% 35 Other Current Receivables is €0.57 Mil as of Mar. 2026. GuruFocus rates FRA:37T with a GF Score™ of 35/100. The stock has 3 warning signs investors should review.

Forte Biosciences's Other Current Receivables for the quarter that ended in Mar. 2026 was €0.57 Mil.

Forte Biosciences's quarterly Other Current Receivables increased from Sep. 2025 (€0.45 Mil) to Dec. 2025 (€0.70 Mil) but then stayed the same from Dec. 2025 (€0.70 Mil) to Mar. 2026 (€0.57 Mil).

Forte Biosciences's annual Other Current Receivables increased from Dec. 2023 (€0.00 Mil) to Dec. 2024 (€0.12 Mil) and increased from Dec. 2024 (€0.12 Mil) to Dec. 2025 (€0.70 Mil).

Forte Biosciences Other Current Receivables Related Terms

Forte Biosciences Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Forte Biosciences's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Forte Biosciences Other Current Receivables Chart

Forte Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial 0.00 0.00 0.00 0.12 0.70

Forte Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.45 0.70 0.57
FRA:37T
35GF Score
Forte Biosciences Inc FRA:37T
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Forte Biosciences Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of €0.57 Mil mean?
Forte Biosciences (FRA:37T) has a Other Current Receivables of €0.57 Mil as of Mar. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Forte Biosciences and its competitors.
Is Forte Biosciences' Other Current Receivables too high?
Forte Biosciences' current Other Current Receivables is €0.57 Mil. Overall, Forte Biosciences has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Forte Biosciences' Other Current Receivables compare to AUTL and SGMT?
Forte Biosciences' Other Current Receivables of €0.57 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Biotechnology company?
A good Other Current Receivables depends on the Biotechnology industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Forte Biosciences and its competitors. Forte Biosciences's current Other Current Receivables is €0.57 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Forte Biosciences stock overvalued right now?
Forte Biosciences (FRA:37T) has a current Other Current Receivables of €0.57 Mil. The current Other Current Receivables is €0.57 Mil. Forte Biosciences' overall GF Score™ is 35/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Forte Biosciences (FRA:37T), the current Other Current Receivables is €0.57 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Forte Biosciences Business Description

Other Exchanges FBRX:USA
Address 3060 Pegasus Park Drive, Building 6, Dallas, TX, USA, 75247
Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.
35GF Score

Get the complete analysis for FRA:37T

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€43.20
Price